Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;52(7):471-484.
doi: 10.1055/a-1172-1352. Epub 2020 Jun 8.

Endocrine Conditions and COVID-19

Skand Shekhar  1   2 , Rachel Wurth  1 , Crystal D C Kamilaris  1 , Graeme Eisenhofer  3 , Francisco J Barrera  4   5 , Michelle Hajdenberg  6 , Joselyne Tonleu  2 , Janet E Hall  2 , Ernesto L Schiffrin  7 , Forbes Porter  8 , Constantine A Stratakis  1 , Fady Hannah-Shmouni  1
Affiliations
Review

Endocrine Conditions and COVID-19

Skand Shekhar et al. Horm Metab Res. 2020 Jul.

Abstract

COVID-19 was declared a global pandemic by the WHO and has affected millions of patients around the world. COVID-19 disproportionately affects persons with endocrine conditions, thus putting them at an increased risk for severe disease. We discuss the mechanisms that place persons with endocrine conditions at an additional risk for severe COVID-19 and review the evidence. We also suggest precautions and management of endocrine conditions in the setting of global curfews being imposed and offer practical tips for uninterrupted endocrine care.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest. Dr. Stratakis laboratory holds patents on the function of the PRKAR1A, PDE11A, and GPR101 molecules and has received research funding from Pfizer Inc. for work related to GPR101 and acromegaly/gigantism.

Figures

Fig. 1
Fig. 1
Clinical impact of endocrine conditions on COVID-19 *Louisiana Department of Health Updates for 3/27/2020. http://ldh.la.gov **ref .
Fig. 2
Fig. 2
Molecular interplay between endocrine conditions, ACE modulation and COVID-19: Illustration of endocrine conditions, mitigating factors and associated risks of COVID-19. Red arrows demonstrate deleterious effects and block arrows reflect inhibition. ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; Ang: Angiotensin; DPP-4: Dipeptidyl peptidase-4.
Fig. 3
Fig. 3
Effects of commonly used drugs in obesity, diabetes mellitus, and hypertension on immune dyregulation. Red arrows indicate negative clinical consequences, green arrows indicate positive clinical implications, black arrows reflect stimulation and block arrows signify inhibition. ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blockers; Ang: Angiotensin; DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon like peptide-1; GC: Glucocorticoids.
See this image and copyright information in PMC

References

    1. WHO Director-General’s opening remarks at the media briefing on COVID-19; 11 March 2020 (press release); 2020
    1. Coronavirus disease (COVID-2019) situation reports (press release). Online, March 16, 2020
    1. Zhou F, Yu T, Du R et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. - PMC - PubMed
    1. Health LDo. Louisiana Department of Health Updates for 3/27/2020 Online: ldh.la.gov; 2020 cited Louisiana Department of Health. Available fromhttp://ldh.la.gov/index.cfm/newsroom/detail/5517
    1. Center ICNAaR. Report on 775 patients critically ill with COVID-19 2020; updated March 27, 2020. Available fromhttps://www.icnarc.org/About/Latest-News/2020/03/27/Report-On-775-Patien...

MeSH terms